Home » Topics » BioWorld Science

BioWorld Science
RSS

Zhejiang Beta Pharma patents fibroblast growth factor receptor inhibitors

Sep. 17, 2018

MaxCyte studies MCY-M11 in phase I for advanced ovarian cancer and peritoneal mesothelioma

Sep. 17, 2018

Gilead Sciences and Precision BioSciences collaborate to develop therapies against HBV

Sep. 17, 2018

Palobiofarma enrolling patients in phase I study of PBF-1129 for NSCLC

Sep. 17, 2018

CymaBay opens enrollment in phase III study of seladelpar for primary biliary cholangitis

Sep. 17, 2018

Glenmark to use Mitra's CANscript platform in support of immuno-oncology pipeline

Sep. 17, 2018

Azitra, The Jackson Laboratory awarded grant to identify compounds for treatment of skin infections

Sep. 17, 2018

Efgartigimod phase II data in ITP support progression to phase III development

Sep. 17, 2018

AstraZeneca adopts Horizon Discovery's Edit-R crRNA libraries for genomics discovery platform

Sep. 17, 2018

FDA approves Ajovy for preventive treatment of migraine

Sep. 17, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...